| HLS on TSXV | Today's Change | Volume | 52 Week Range (Low/Hi) | Market Cap |
| 9.20CAN | -0.10/-1.08% | 18,000 | 2.30 / 11.89 | 252.36 M |
Contact Information
HLS Therapeutics Inc.
Headquarters:10 Carlson Court, Suite 410
Etobicoke, Ontario
Canada, M9W 6L2
Tel: 647-495-9000
Fax: 416-213-0045
Email: Send a message
Website: Visit website
For more information...
Lead: Laura Welsh| Jun 6, 2018 - 1:00 PM PDT |
Corporate Presentation - Vancouver |
|
| Jun 7, 2018 - 12:00 PM MDT |
Corporate Presentation - Calgary |
HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established, branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.
Greg Gubitz, BA, LLB - Chief Executive Officer
Gilbert Godin, BEng, MBA - President and Chief Operating Officer
Joe MacLean, BCom, LLB - Director, Corporate Development
Tim Hendrickson, MBA - VP Finance & Administration
Hemanth Varghese, PhD - Head of Corporate Strategy and Business Development
Ryan C. Lennox BA,JD - General Counsel
Sanjiv Sharma, MBA - VP Commercial Operations
Jason A. Gross, PharmD - VP Scientific Affairs
Carmel Daughtery, PMP - VP Integration Management
Bill Wells, BA, MBA - Executive Chairman of the Board
Greg Gubitz, BA, LLB - Chief Executive Officer
J. Spencer Lanthier - Director, Independent
Yvon Bastien - Director, Independent
Daniel Tassé - Director, Independent
Don DeGolyer - Director, Independent
Rodney Hill - Director, Independent
Stock Information
Events
| Jun 6, 2018 - 1:00 PM PDT |
Corporate Presentation - Vancouver |
|
| Jun 7, 2018 - 12:00 PM MDT |
Corporate Presentation - Calgary |
Press Releases
Company Overview
HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established, branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.
Management
Greg Gubitz, BA, LLB - Chief Executive Officer
Gilbert Godin, BEng, MBA - President and Chief Operating Officer
Joe MacLean, BCom, LLB - Director, Corporate Development
Tim Hendrickson, MBA - VP Finance & Administration
Hemanth Varghese, PhD - Head of Corporate Strategy and Business Development
Ryan C. Lennox BA,JD - General Counsel
Sanjiv Sharma, MBA - VP Commercial Operations
Jason A. Gross, PharmD - VP Scientific Affairs
Carmel Daughtery, PMP - VP Integration Management
Board of Directors
Bill Wells, BA, MBA - Executive Chairman of the Board
Greg Gubitz, BA, LLB - Chief Executive Officer
J. Spencer Lanthier - Director, Independent
Yvon Bastien - Director, Independent
Daniel Tassé - Director, Independent
Don DeGolyer - Director, Independent
Rodney Hill - Director, Independent
Contact Information
10 Carlson Court, Suite 410
Etobicoke, Ontario
M9W 6L2, Canada
Telephone: 647-495-9000
Fax: 416-213-0045
Email: Send a message
Website: Visit website